The coupling of neural activity and increased blood flow (neurovascular coupling) is vital to brain function. Failure of this coupling occurs early in Alzheimer?s disease (AD) and ?pure? tauopathies and induces chronic brain injury, contributing to neurodegeneration.Amongothermediators,neurovascularcouplingisregulatedby nitric oxide (NO) bioavailability. NO formed by the neuronal form of nitric oxide synthase (nNOS) is central to neurovascular coupling, and its production by nNOS-expressing interneurons depends on microtubule- dependenttransportofnNOStodendrites.Tauprotein,causallyimplicatedinAD,stabilizesmicrotubules.Under pathologic conditions, hyperphosphorylated tau detaches from microtubules, destabilizing the microtubule cytoskeleton. Soluble hyperphosphorylated tau aggregates transfer trans-neuronally, promoting native tau phosphorylation and microtubule destabilization in target cells. Among the neuron types targeted by tau pathology in AD are vasculature-associated nNOS-expressing neurons. The functional impact of pathogenic tauonnNOSneurons,anditscontributiontobrainvasculardysfunctioninAD,havenotbeenexploredandare not understood. The objective of this proposal is to define mechanisms of pathogenic tau-induced brain vascular dysfunction and determine whether removing pathogenic tau with immunotherapy is a potential treatmentforAD.Wehypothesizethatsolubletauaggregatescriticallycontributetobrainvasculardysfunction in AD by blocking nNOS activation, and that removal of soluble tau aggregates with immunotherapy will prevent and potentially treat brain vascular dysfunction by restoring nNOS activity. Our studies show that aggregation-prone human tau causes neurovascular coupling deficits driven by reduced nNOS activation in modelsofADtauopathy;?andthattransmissionofsolubleaggregatedtauintoneuronsblocksnNOSactivation, suggestingthatpathogenictaudrivesbraindysfunctionbyimpairingnNOS.Wewilltestourcentralhypothesis by pursuing two Specific Aims.
In Aim 1, we will define the mechanisms by which soluble tau aggregates impede nNOS activation using in vitro approaches, and identify molecular alterations triggered by tau aggregates in vivo in microvasculature-associated neurons during disease progression in a mouse model of AD tauopathy.
In Aim 2, we will establish the therapeutic potential of soluble aggregated tau removal in AD cerebrovasculardysfunction,usingantibody-basedremovalofsolubletauaggregatesearlyinADprogression and after disease onset, and determine, in human AD brains, how accumulation of tau aggregates and molecular alterations identified in Aim 1 correlate with AD histopathology and progression. The role of tau in AD cerebrovascular dysfunction is unexplored. As a result of the work proposed, we expect to (a) identify solubletauaggregate-inducedmolecularalterationsthatdiminishnNOSactivity,(b)definetheimpactofnNOS impairment by soluble aggregated tau in cerebrovascular deficits of AD, and (c) evaluate whether tau immunotherapymayhavepromiseforAD.Theseresultsareexpectedtomarkedlyadvanceourunderstanding ofhowpathogenictau,andcellulareventsittriggers,canbetargetedfortherapeuticpurposes.Inaddition,this study will contribute novel insights into the role of tau in cerebrovascular dysfunction of AD and other tauopathies.Equallyimportant,theresultsofthisstudywillhaveapositiveimpactbecausetheidentificationof solubleaggregatedtauasadriverofADcerebrovasculardysfunctionwillrevealnoveltargetsfortherapiesand propelforwardnewresearchincerebrovascularbiologyandneurodegeneration.

Public Health Relevance

Energysubstratesneedtobedeliveredtoactiveareasofthebrain?ondemand?throughitsbloodsupply.Failure ofcouplingbetweenneuralactivityandincreasedbloodflow(neurovascularcoupling,NVC),vitaltobrainfunction, occurs early in Alzheimer?s disease (AD) and ?pure? tauopathies. Our studies will define how transmission of pathogenictauprotein,causallyimplicatedinAD,intospecializedneuronsassociatedwithbrainvasculaturedrives NVC failure in models of AD tauopathy by blocking the activation of the neuronal form of nitric oxide synthase, criticaltotheNVCresponse.BecausetheroleoftauinADbrainvasculardysfunctionisunexplored,ourstudies willrevealnovelmediatorsofcerebrovasculardysfunctioninAD,identifynoveltargetsfortherapies,andpropel forwardnewresearchincerebrovascularbiologyandneurodegeneration.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
2I01BX002211-05A1
Application #
9892784
Study Section
Special Emphasis Panel (ZRD1)
Project Start
2015-01-01
Project End
2023-12-31
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
South Texas Veterans Health Care System
Department
Type
DUNS #
078493228
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Jahrling, Jordan B; Lin, Ai-Ling; DeRosa, Nicholas et al. (2018) mTOR drives cerebral blood flow and memory deficits in LDLR-/- mice modeling atherosclerosis and vascular cognitive impairment. J Cereb Blood Flow Metab 38:58-74
Van Skike, Candice E; Galvan, Veronica (2018) A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review. Gerontology 64:205-211
Ungvari, Zoltan; Tarantini, Stefano; Donato, Anthony J et al. (2018) Mechanisms of Vascular Aging. Circ Res 123:849-867
Castillo-Carranza, Diana L; Nilson, Ashley N; Van Skike, Candice E et al. (2017) Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies. Aging Dis 8:257-266
Marinesco, Stephane; Ungvari, Zoltan; Galvan, Veronica (2017) Age-related impairment of metabovascular coupling during cortical spreading depolarizations. Am J Physiol Heart Circ Physiol 313:H1209-H1212
Tarantini, Stefano; Fulop, Gabor A; Kiss, Tamas et al. (2017) Demonstration of impaired neurovascular coupling responses in TG2576 mouse model of Alzheimer's disease using functional laser speckle contrast imaging. Geroscience 39:465-473
Lin, Ai-Ling; Jahrling, Jordan B; Zhang, Wei et al. (2017) Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease. J Cereb Blood Flow Metab 37:217-226
Csiszar, Anna; Tarantini, Stefano; Fülöp, Gábor A et al. (2017) Hypertension impairs neurovascular coupling and promotes microvascular injury: role in exacerbation of Alzheimer's disease. Geroscience 39:359-372
Galvan, Veronica; Hart, Matthew J (2016) Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. Biochim Biophys Acta 1862:992-1007
Cremers, Claudia M; Knoefler, Daniela; Gates, Stephanie et al. (2016) Polyphosphate: A Conserved Modifier of Amyloidogenic Processes. Mol Cell 63:768-80

Showing the most recent 10 out of 12 publications